Rocket Pharmaceuticals Reports Q3 2026 Results, $279.4 Million in Cash

Rocket Pharmaceuticals reported a third-quarter 2026 net loss of $49.2 million, or $0.43 per share, compared with a $50.3 million loss, or $0.45 per share, a year earlier. Cash, cash equivalents and investments totaled $279.4 million at September 30, 2026. The company said its cash position is expe…